Why 4/5: Directly addresses prescription drug costs, a major financial concern for healthcare consumers.
This bill establishes a Prescription Drug Affordability Advisory Panel to analyze drug pricing trends and recommend policies to improve affordability. It also prohibits drug manufacturers and wholesale distributors from selling certain drugs above a federally established maximum fair price, with civil penalties of $10,000 per violation.
Third reading
Read third time
Update
Commerce and Labor Substitute rejected
Update
Finance and Appropriations Substitute agreed to
Substitute adopted
Engrossed by Senate - committee substitute
Passed a chamber
Passed Senate with substitute (34-Y 6-N 0-A)
Substitute adopted
Senate substitute agreed to by House (87-Y 11-N 0-A)
Update
Fiscal Impact Statement from Department of Planning and Budget (HB483)
Enrolled
Enrolled
Passed a chamber
Bill text as passed House and Senate (HB483ER)
This bill has passed its votes and is headed to the Governor's desk. You still have a say — the Governor's office reads messages before deciding whether to sign.
New to all this? See how a bill becomes law →
Summarized from the official bill text (“Prescription Drug Affordability Board; established.”) · Read the actual bill →
Passed a chamber
Signed by President
Update
Fiscal Impact Statement from Department of Planning and Budget (HB483)
Passed a chamber
Signed by Speaker
Enrolled
Enrolled Bill communicated to Governor on March 31, 2026
Sent to the Governor
Governor's Action Deadline 11:59 p.m., April 13, 2026
Line-item veto
Governor's recommendation received by House